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Inflammation plays a major role in the pathophysiology of lung disease in CF. This response is probably triggered primarily as a reaction
to the inability of the affected lung to resist the invasion of the most common bacterial pathogens seen in this disease, namely, Staphylococcus
aureus, Haemophilus influenzae and Pseudomonas aeruginosa. Debate continues as to whether there may or may not be a pre-inflammation
of the lungs as part of the basic functional defect of CFTR.
The anti-inflammatory treatment modalities most tested to date are: oral corticosteroids, effective but associated with significant long-term
side effects, inhaled corticosteroids, so far not proven to be effective probably because of difficulty with absorption through the viscid surface
secretions of the lung and ibuprofen, potentially effective but inhibited by the need to monitor drug levels invasively and potential
gastrointestinal side effects. The most promising newcomer is macrolide antibiotics such as azithromycin acting as a long-term anti-
inflammatory agent with an excellent safety profile.
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Inflammation is a major pathophysiological feature of
chest disease in cystic fibrosis. A number of hypotheses
have been put forward as to its possible aetiology. The
abnormal CFTR, particularly that which is found in
homozygous delta F508 patients, is probably also involved
in this pro-inflammatory process [1]. One of the most
characteristic changes of inflammation in CF is a large
infiltration by neutrophils into the lung parenchyme. These
cells produce a number of local tissue damaging products,
particularly elastase, which causes long-term structural
airway damage. When the neutrophils degenerate DNase is
released from the nuclei and this contributes to the
increased viscosity of sputum which is characteristic of
the illness. Armstrong et al. [2] have suggested that
inflammation may even precede infection in this disease.
This has also been suggested by the presence of increased
neutrophils and cytokines such as IL-8 detected in young
infants with cystic fibrosis with no overt evidence of1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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that anti-inflammatory therapy could play an important role
in the long-term management of the illness aimed at
limiting the degree and severity of lung damage over a
period of years.
Anti-inflammatory therapy can be provided in various
forms. These include the use of oral corticosteroids which
are potentially highly effective but which carry with them
the risk of long-term systemic side effects. Inhaled cortico-
steroids also have considerable potential because of their
local action within the lung. Their potential therapeutic
disadvantage is the difficulty of penetrating the viscid
mucus which lines the airway in CF patients particularly as
the disease progresses. Potentially higher doses than those
currently licensed for clinical use might be needed in order
to produce a clinical response. Other anti-inflammatory
agents such as ibuprofen have considerable potential and
have been the subject of various studies over the years.
More recently macrolides have come forward as potent anti-
inflammatory agents and are beginning to have an estab-
lished place in the therapeutic regimen for patients with
long-term Pseudomonas infection. Other agents which have
been used include immunoglobulins and dornase alphas 4 (2005) 45 – 48ed by Elsevier B.V. All rights reserved.
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as being mucolytic. Montelukast a cysteinyl-leukotriene
receptor antagonist is also under study.2. Oral corticosteroids
In 1985 Auerbach et al. [4] reported the results of a study
in which patients were given 2 mg/kg of prednisone on
alternate days during a 4-year period. This was a double
blind placebo controlled trial including 45 children aged 1–
12 years. The steroid group had better maintained lung
function including FVC and FEV1, better growth velocity in
terms of height and weight and less inflammation as
assessed by ESR and serum IgG. They also had fewer
admissions to hospital with acute exacerbations of the
underlying disease. Adverse effects or non-compliance was
however a significant problem and as many as 25% of
patients failed to complete the study protocol. Later reported
side effects included growth impairment, glucose intoler-
ance, early cataract formation, bone fractures and cush-
ingoid appearance [5].
A subsequent large multicentre North American Study
was reported by Eigen et al. in 1995 [6]. Two hundred and
eighty five patients aged 8–14 were randomised into a 4-
year double blind placebo controlled study. Treatment
consisted of either 1 or 2 mg/kg/day of prednisone. A
significant incidence of side effects occurred in the 2-mg/kg
alternate day group including glucose intolerance, cataract
formation and impaired growth [7]. Similar side effects
subsequently emerged later in the lower dose group as well.
These studies [6] showed that at 1 mg/kg on alternate days,
there was a significant improvement in FVC after 6 months
in those who were chronically infected with Pseudomonas
aeruginosa. Impaired growth only became evident after 2
years of treatment. In this study there was no reduction in
the rate of hospitalisation between treatment groups. Recent
studies have highlighted the prevalence of osteoporosis as a
long-term complication in CF [8]. This would therefore be a
further contraindication to the long-term use of oral
corticosteroids to control the chronic lung disease in CF.
At the present time therefore these agents cannot be
recommended for the overall control of this aspect of the
underlying disease process.
There are however other situations in CF where long-
term oral steroids can be helpful in suppressing complica-
tions including chronic allergic bronchopulmonary asper-
gillosis (APBA) and concomitant moderate or severe asthma
which does occur in a small but significant sub-group of
patients [9].
Because of their powerful anti-inflammatory effects, oral
corticosteroids can be very useful in the management of
acute pulmonary exacerbations of CF lung disease. In this
situation they are used in conjunction with intensive
intravenous antibiotic therapy as well as bronchodilators,
mucolytics such as DNase and appropriate modes of chestclearance techniques depending on the patients age, severity
of lung involvement and ability to cooperate with the
relevant treatment modalities.3. Inhaled corticosteroids
The evidence for the role of inhaled corticosteroids
remains largely unproven in the long-term management of
patients with CF. Theoretically they have considerable
potential benefit as long-term anti-inflammatory agents. A
small number of studies have been undertaken to assess the
use of these agents with varying results [5,10]. A significant
proportion of CF patients do however receive them on a
regular basis as part of their therapeutic regimen.
Shiotz et al. [11] reported on 26 patients aged 4–29
given Beclomethasone diproprionate 400 mcg/day in a
double blind placebo-controlled trial over 16 weeks. All
patients were infected with P. aeruginosa. No significant
effects of treatment were seen. The lack of therapeutic effect
was thought to be due either to inadequate dosage of the
drug or its inability to penetrate the highly viscid lung
secretions of the CF patient. Van Haren et al. [12] reported
on 12 adult patients given 1600 mcg of budesonide versus
placebo over 6 weeks. This resulted in an improvement in
bronchial hyperresponsiveness but not in basic spirometry.
The patients also reported a decrease in cough during the
treatment period.
Balfour-Lynn et al. [10] reported on a double blind
placebo randomised crossover trial of fluticasone propionate
(400 mcg/day) given for a 6-week period in 23 children with
CF aged 7–17 years. No measurable therapeutic benefit was
seen during the active treatment period. Neither atopic
status, baseline FEV1 nor concomitant DNase therapy had
any effect on treatment response.
Skov et al. [13] also reported that the combination of
budesonide therapy with itraconazole to treat allergic
bronchopulmonary aspergillosis resulted in adrenal insuffi-
ciency in 11 of 25 patients studied. This was reversible
when itraconazole was discontinued. It is thought that
itraconazole caused an increase in systemic budesonide
concentration and an associated inhibition of adrenocorti-
coid hormone secretion.
Inhaled corticosteroids might be more effective in young
children before significant hyperviscosity of lung secretions
has developed. Wojtczak et al. [14] reported on a 2-month
trial of Beclomethasone in infants. This resulted in a
decrease in lower airway neutrophils but did not show any
adverse effects on the adrenal glands.
The precise role of inhaled corticosteroids in the long-
term management of CF lung at all ages thus remains to be
elucidated.
Inhaled steroids are widely used for the treatment of
patients with significant CF lung disease but as yet there are
few convincing properly powered studies demonstrating
long-term efficacy. They may however have a particular role
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is bronchial hyper-reactivity [15,16].4. Ibuprofen
Ibuprofen is a substance known to have significant anti-
inflammatory effects principally effected through a direct
action on inhibiting the motility, adherence and localised
aggregation of neutrophils within the lung tissue itself.
Konstan et al. [17] reported on a double blind trial of high
dose ibuprofen in 85 CF patients aged 5–39 years. The
patients had relatively mild lung disease with FEV1>60%
predicted. The trial lasted for 4 years. Those given active
treatment had a slower annual rate of decline of FEV1 than
those given placebo (P=0.02) and weight (as a percentage
of ideal body weight) was better maintained over this time
period in the actively treated group. There was no
significant difference between the two groups in the
frequency of hospitalisation. The beneficial effects were
most evident in those aged 5–12 years.
This treatment regimen requires regular measurements
of ibuprofen plasma levels. There was also concern about
possible long-term side effects such as a small risk of
gastrointestinal haemorrhage. Despite the results of this
study ibuprofen is not used by many CF centres as
standard treatment; less than 10% in the US [17] and less
than 1% in the UK.5. Macrolides
One of the most interesting new anti-inflammatory
therapies introduced in recent years is the use of macrolides,
particularly azithromycin. The agents are thought to act by
suppressing pro-inflammatory cytokines and causing direct
alterations in the function of neutrophils [18,19]. There have
been three randomised controlled trials of azithromycin
versus placebo in patients with CF [20–22]. A meta-
analysis of these studies demonstrated a significant
improvement or maintenance of FEV1 and FVC in treated
patients versus controls after 6 months of therapy. There was
no reduction in the need for intravenous antibiotic therapy
or days of hospitalisation in any of these studies.
There is evidence to suggest that the use of azithromycin
on a regular basis does produce a small but significant
improvement in lung function over a period of time. Side
effects such as mild disturbance of liver function tests are
rare. Azithromycin probably does have a useful therapeutic
role in patients with moderate to severe lung disease.6. Immunoglobulins
A recent retrospective case note review of 16 children
aged 3–16 years with advanced CF (Balfour-Lynn et al.,2003) demonstrated a significant improvement in FVC with
an average increase of 13% (P <0.05) when given monthly
therapy for a median duration of 7.5 months. FEV1 was
unchanged but the total daily dose of inhaled corticosteroid
was reduced from a median of 2000 mcg/day by a median
change of 400 mcg/day (P <0.05). This therapy was
generally well tolerated although occasional side effects
including headache, fever, hypertension, aseptic meningitis
and chest tightness were reported. The total daily dose of
oral Prednisolone was reduced from 0.6 mg/kg/day by a
median amount of 0.6 mg/kg/day (P <0.007) thus in this
series it was possible to discontinue oral steroid therapy
completely in 16 of the children studied. This therapeutic
regimen may therefore have a use in individual patients with
advanced chest disease and may be effective in reducing the
need for both oral and inhaled corticosteroids.7. Other agents
A number of other possible anti-inflammatory agents are
currently under investigation for this group of patients.
These include recombinant human dornase alpha (DNase)
[23] and Montelukast, a cysteinyl-leukotriene receptor
antagonist [24].8. Conclusions
Anti-inflammatory therapy has a logical basis as part of
the overall treatment of CF lung disease. As well as
reducing the effects of the neutrophil burden on the lungs
by inhibition of locally active cytokines, these agents can
have acute beneficial effects such as those seen in asthma.
These can result in improved airway calibre by reduction of
mucosal oedema and stabilisation of airway narrowing as a
result of acute bronchospasm. Oral corticosteroids are also
vital for the control of other lung related complications such
as allergic bronchopulmonary aspergillosis (ABPA).
Inhaled corticosteroids delivered in sufficient amounts
are known to be powerfully anti-inflammatory in asthma.
Their role in the long-term management of CF lung disease
has yet to be defined. A number of studies using conven-
tionally approved dosage schedules have failed to show
significant benefit in the long-term. It may be that much
higher doses are required in order to penetrate the thick
surface epithelial mucus layer seen in those with advanced
CF lung disease before therapeutic efficacy is reached.
Given the relatively good safety profile of these agents,
further studies of their use are warranted.
The use of other anti-inflammatory agents such as
ibuprofen has been elucidated by carefully controlled
clinical studies. The varying bioavailability of the drug
and the consequent need to monitor blood levels on a
regular basis have inhibited its widespread use by CF
clinicians. The potential for gastrointestinal side effects
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clinical use.
Intravenous immunoglobulin may have a place in
selected patients especially those dependent on long-term
oral corticosteroid therapy. Long-term macrolides especially
azithromycin do appear to have a place in the treatment of
patients with moderate to severe CF lung disease.
Macrolides such as azithromycin have recently come into
use because of their anti-inflammatory role in patients with
long-term Pseudomonas infection. Controlled clinical trials
have increasingly shown benefit over significant periods of
time in these patients. The once daily dosage regimen and
their excellent safety profile will no doubt result in their
increasing use with time.
A number of other promising anti-inflammatory agents
which hold considerable potential for future use are
currently under investigation.References
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